Research Presented by Dr. Thomas Stricker Suggests Oncologists Should Switch to Targeted Treatment if Biomarker Testing Identifies Actionable Mutation Even After First-Line Treatment on Non-targeted treatment Has Begun Research Led by Dr. Gregory Vidal Evidences Identifies Inequities by…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.